Kunyan Li

发表

Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers

Xue Chen, Feng Yang, Jiao Zhao, 2021, Cancer Chemotherapy and Pharmacology.

Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.

A. Mansfield, L. Zeng, N. Yang, 2020, European journal of cancer.

Pharmacokinetic and bioequivalence study of new S-1 capsule in Chinese cancer patients.

N. Yang, Y. Bai, Qiming Wang, 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Can CT Radiomics Detect Acquired T790M Mutation and Predict Prognosis in Advanced Lung Adenocarcinoma With Progression After First- or Second-Generation EGFR TKIs?

Xiaoping Yu, Chao Fang, M. Gong, 2022, Frontiers in Oncology.

Mast cells induce epithelial-to-mesenchymal transition and migration in non-small cell lung cancer through IL-8/Wnt/β-catenin pathway

N. Yang, T. Cheng, Jianfu Heng, 2019, Journal of Cancer.

Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy

Steven H. Lin, Douglas B. Johnson, Y. Lou, 2022, Journal for ImmunoTherapy of Cancer.

Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy.

G. Mills, Steven H. Lin, Y. Lou, 2021, Journal of the National Cancer Institute.

Efficacy of Joungal in preventing febrile neutropenia induced by platinum-based doublet chemotherapy in lung cancer.

Yongchang Zhang, A. Lizaso, Kunyan Li, 2020, Annals of palliative medicine.

Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non–Small Cell Lung Cancer After Second-Line Treatment Failure

L. Zeng, Chunhua Zhou, N. Yang, 2020, JAMA network open.

Anticancer drug R&D landscape in China

Bing-he Xu, Y. Ba, L. Shen, 2020, Journal of Hematology & Oncology.

Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.

A. Mansfield, L. Zeng, Chunhua Zhou, 2020, Lung cancer.

The new Good Clinical Practice-2020 in China: Views from ethical perspective

Feng Yang, Jianfu Heng, Kunyan Li, 2021, The Lancet regional health. Western Pacific.

A Randomized, Open, Single-Centre, Crossed Study of the Effect of Food on the Pharmacokinetics of One Oral Dose of Alflutinib Mesylate Tablets (AST2818) in Healthy Male Subjects

N. Yang, Xue Chen, Qi Tang, 2020, Iranian journal of pharmaceutical research : IJPR.

Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers.

N. Yang, Xue Chen, Jiao Zhao, 2021, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

The efficacy and safety of taletrectinib in patients with TKI-naïve or crizotinib-pretreated ROS1-positive non–small cell lung cancer (NSCLC).

Yunpeng Liu, N. Yang, M. Tao, 2022, Journal of Clinical Oncology.

Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced solid tumors.

Yunpeng Liu, L. Shen, J. Gong, 2021 .

SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for advanced NSCLC with EGFR mutations: Data from a multicenter phase 1 study.

Yunpeng Liu, Yuankai Shi, Jifeng Feng, 2021 .

Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST.

N. Yang, M. Tao, Caicun Zhou, 2021 .

SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial.

Jun Zhu, S. Hao, Kunyan Li, 2022, The Lancet. Haematology.

Benefit assessment of extended dosing in cancer patients after their withdrawal from clinical trials

Jianfu Heng, Kunyan Li, Feng Yang, 2023, Frontiers in pharmacology.